Bovenden - Lenglern, Germany

  • Featured

    Flexible-Dose Trial in Early Parkinson's Disease (PD)

    Phase

    3

    Span

    256 weeks

    Sponsor

    Cerevel Therapeutics, LLC

    Sydney

    Recruiting

  • Featured

    TemPo Studies

    **All eligible study participants will receive at no cost:** • Study-related consultation and care • Study visits, tests, assessments, and procedures • Study drugs (investigational drug or placebo)

    Phase

    N/A

    Span

    212 weeks

    Sponsor

    Cerevel Therapeutics

    Sydney, New South Wales

    Recruiting

1-2 of 2